Literature DB >> 12219025

Interferon-gamma gene polymorphisms and the development of sepsis in patients with trauma.

Nicole A Stassen1, Lisa A Leslie-Norfleet, Ann M Robertson, M Robert Eichenberger, Hiram C Polk.   

Abstract

BACKGROUND: The outcome of patients with trauma does not always correlate with injury severity or premorbid health status. This study evaluates the relationship between polymorphisms in the first intron of the interferon-gamma gene and the development of sepsis after trauma.
METHODS: DNA was extracted from peripheral leukocytes of patients with trauma and an injury severity score of 16 or greater. Data collected included demographics, injury mechanism, injuries sustained, development of sepsis, and outcome. A previously identified cytosine/adenine repeated polymorphism was amplified, alleles/genotypes identified, and the results correlated with patient outcome.
RESULTS: Sixty-one patients were evaluated. Thirty patients (49%) became septic. The injury severity score, race, age, and gender distribution was similar for both the septic and nonseptic groups. Six alleles and 10 genotypes were identified. Alleles C (34%) and D (52%) were the most common. Patients who were septic had a 62% chance of having a D allele (P =.06), whereas they had only a 29% chance of having a C allele. Homozygotes for allele D (DD) were the most likely to become septic (65%).
CONCLUSIONS: Homozygotes for the D allele (DD) of the interferon-gamma gene have an increased chance of developing sepsis after traumatic injury compared with other allelic combinations. This supports the hypothesis that genetic composition plays a role in patient outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12219025     DOI: 10.1067/msy.2002.127167

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

1.  Ethical considerations in the collection of genetic data from critically ill patients: what do published studies reveal about potential directions for empirical ethics research?

Authors:  B D Freeman; C R Kennedy; H L Frankel; B Clarridge; D Bolcic-Jankovic; E Iverson; E Shehane; A Celious; B A Zehnbauer; T G Buchman
Journal:  Pharmacogenomics J       Date:  2009-12-08       Impact factor: 3.550

Review 2.  Genetic determinants and ethnic disparities in sepsis-associated acute lung injury.

Authors:  Kathleen C Barnes
Journal:  Proc Am Thorac Soc       Date:  2005

Review 3.  Role of cytokines as a double-edged sword in sepsis.

Authors:  Hina Chaudhry; Juhua Zhou; Yin Zhong; Mir Mustafa Ali; Franklin McGuire; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  In Vivo       Date:  2013 Nov-Dec       Impact factor: 2.155

4.  Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients.

Authors:  Julia Brenmoehl; Hans Herfarth; Thomas Glück; Franz Audebert; Stefan Barlage; Gerd Schmitz; Dieter Froehlich; Stefan Schreiber; Jochen Hampe; Jürgen Schölmerich; Ernst Holler; Gerhard Rogler
Journal:  Intensive Care Med       Date:  2007-06-09       Impact factor: 17.440

5.  Genetic polymorphisms and posttraumatic complications.

Authors:  Wei Gu; Jianxin Jiang
Journal:  Comp Funct Genomics       Date:  2011-01-11

Review 6.  [Gene polymorphism in intensive care patients. Is the course of disease predetermined?].

Authors:  S Ziegeler; S Kleinschmidt; C D Collard
Journal:  Anaesthesist       Date:  2004-03       Impact factor: 1.041

7.  Developing a gene expression model for predicting ventilator-associated pneumonia in trauma patients: a pilot study.

Authors:  Joseph M Swanson; G Christopher Wood; Lijing Xu; Lisa E Tang; Bernd Meibohm; Ramin Homayouni; Martin A Croce; Timothy C Fabian
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

8.  Functional polymorphisms of interferon-gamma affect pneumonia-induced sepsis.

Authors:  Ding Wang; Xuan Zhong; Dongjian Huang; Rui Chen; Guibin Bai; Qing Li; Bolan Yu; Yong Fan; Xiaofang Sun
Journal:  PLoS One       Date:  2014-01-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.